REN 001 - Rocket Pharmaceuticals
Alternative Names: REN-001 - Rocket PharmaceuticalsLatest Information Update: 18 Oct 2023
At a glance
- Originator Renovacor
- Developer Rocket Pharmaceuticals
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action BAG3 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dilated cardiomyopathy
Most Recent Events
- 18 Oct 2023 REN 001 is still in preclinical trials for Dilated cardiomyopathy in USA (Intracoronary) (Rocket Pharmaceuticals pipeline, October 2023)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Dilated cardiomyopathy in USA (Intracoronary)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Dilated cardiomyopathy in USA (Intracoronary)